Coherus, Junshi: Positive Results in Phase 3 cancer combo trial

 Toripalimab in combination with chemotherapy was associated with significant improvements in PFS and OS compared with chemotherapy alone in patients with advanced NSCLC without EGFR/ALK mutations, regardless of PD-L1 expression

– Supports combination development of toripalimab plus anti-TIGIT in NSCLC and other solid tumor indications

https://www.biospace.com/article/coherus-and-junshi-biosciences-announce-publication-of-positive-results-from-choice-01-a-phase-3-clinical-trial-evaluating-toripalimab/